Researchers at Tel Aviv University (TAU) have successfully treated autism in animal models with medical cannabis oil. The researchers found that this treatment improves both behavioral and biochemical parameters of autism.

The study was led by PhD student Shani Poleg and Professor Daniel Offen of TAU’s Sackler Faculty of Medicine, Felsenstein Medical Research Center, and Sagol School of Neuroscience and was published in Translational Psychology.

“The usual process for testing new medications involves research in petri dishes, followed by animal models and finally a clinical study in humans,” Professor Offen explains. “With medicinal cannabis, however, the process has been reversed: Treatments began in humans. Since cannabis is not defined as a medication, trials have already been conducted in children and adolescents with autism without any preliminary studies addressing issues like the effect of cannabis on biochemical processes in the brain, spinal fluid, or blood. There is a great deal of misinformation on the subject of medicinal cannabis and autism, and Shani Peleg’s doctoral project represents pioneering basic research with regard to treating autism with cannabis oil.”

Watch the researchers describe the research:

Autism is a neurodevelopmental disease, and its main symptoms are social deficiencies and compulsive behaviors. Cases range from mild to severe, and causes are both genetic and environmental. A mutation in a single gene, called Shank3, is associated in about 1% of all autism cases. In the current study, researchers at TAU used animal models with a mutation in Shank3 to test the effectiveness of cannabis oil for alleviating symptoms of autism.

“We saw that cannabis oil has a favorable effect on compulsive and anxious behaviors in model animals,” Poleg says. “According to the prevailing theory, autism involves overarousal of the brain which causes compulsive behavior. In the lab, in addition to the behavioral results, we saw a significant decrease in the concentration of the arousing neurotransmitter glutamate in the spinal fluid, which can explain the reduction in behavioral symptoms.”

Attempting to determine which components of cannabis oil alleviate symptoms of autism, the researchers found that THC, responsible for the euphoric sensation associated with the use of cannabis, is effective in treating autism, possibly even in small quantities.

“Clinical trials testing cannabis treatments for autism usually involve strains containing very large amounts of CBD – due to this substance’s anti-inflammatory properties, and because it does not produce a sense of euphoria,” Poleg says. “Moreover, the strains used for treating autism usually contain very little THC, due to apprehension regarding both the euphoria and possible long-term effects.

“In the second stage of our study we inquired which active substance in cannabis causes the behavioral improvement, and were surprised to discover that treatment with cannabis oil that contains THC but does not contain CBD produces equal or even better behavioral and biochemical effects. Moreover, our results suggest that CBD alone has no impact on the behavior of model animals.

“This is of course an initial study,” Poleg concludes. “But we hope that through our basic research we will be able to improve clinical treatments. Our study shows that when treating autism with medicinal cannabis oil there is no need for high contents of either CBD or THC. We observed significant improvement in behavioral tests following treatments with cannabis oil containing small amounts of THC and observed no long-term effects in cognitive or emotional tests conducted a month and a half after the treatment began.”